ARCHIVES

Improved NCI Relations With FDA Cited As Model For Government Accord, Lasagna Committee Says

This article is from The Cancer Letter archive.

Vol. 16 No. 16 | April 20, 1990

Download PDF Visit The Full Archive

Related Articles

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

July 25, 2014

New Carfilzomib Combination Produces Near Remissions

June 29, 2012

Final stats On FY92 Budget; Success Rate Was 35 Percent

December 4, 1992

In Brief: Elion, Schein, Johnson Head Societies; Phillips, Salmon Elected; McIntire, Pistenma to Leave NCI

June 3, 1983

NCI to Study Review Group’s report Urging Restructure of Prevention Programm

June 27, 1997

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013